DGDaniel Gil-Alós

Daniel Gil-Alós

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Gil-Alós has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Progressive Multifocal Leukoencephalopathy in Lymphoid Malignancies: A Multicenter GELTAMO Case Series

    by Anna Martín-Carrizosa, Cristina García-Herce, David Quintela Vilchez, Juan Carlos Caballero Hernáez, Rocio Figueroa Mora, Olatz Olabarri Etxebarria, David Alonso-Castronuño, Daniel Gil-Alós, Seila Cerdá Rodríguez, Lucía Núñez Martín-Buitrago, et al.

  • Open Access

    Mass Spectrometry Profiling of Therapeutic Antibodies in Multiple Myeloma: m/z Features and Concordance with Immunofixation Electrophoresis

    by Rosa Pello, María Ángeles Iglesias, Raúl Vidal, Raúl Mateos, Marta Outón, Cristina Agulló, Nerea Varo, Alberto Blanco-Sánchez, Nieves López-Muñoz, Álvaro García, et al.

    Background/Objectives: Therapeutic monoclonal antibodies, including bispecifics (t-mAbs), can interfere with serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE), mimicking residual M-protein. We evaluated a mass spectrometry (MS; EXENT®)-based workflow supported by an m/z reference library to discriminate drug from disease and assess concordance with IFE. Methods: Fifty-eight serum samples from 29 multiple myeloma patients were analyzed at baseline and after 3 months. Targeted enrichment of t-mAbs followed by MS enabled detection of peaks annotated through matching to a theoretical m/z panel and correlation with SPEP/IFE results. Results: Comparison of IFE versus MS showed 11/29 (38%) double positives, 15/29 (52%) double negatives, and 3/29 (10%) IFE−/MS+; no IFE+/MS− cases were observed. Using MS as a reference, IFE exhibited 78.6% sensitivity and 100% specificity. The m/z library enabled attribution of interference to linvoseltamab (n = 9), daratumumab (n = 6), and teclistamab (n = 3); in 16 patients treated with other bispecifics, no drug-related peaks were detected after 3 months. Longitudinal analysis discriminated therapeutic from endogenous immunoglobulins, identified baseline M-protein, and prevented false residual signals. Conclusions: MS (EXENT®)-based characterization of t-mAbs improves response monitoring accuracy in multiple myeloma and supports integration of MS into routine laboratory practice.


  • Open Access

    GMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia

    by Laura Córdoba-Espejo, Laura Sánchez-Vega, Almudena García-Ortiz, Eva Castellano, Raquel Oliva, Alejandra Ortiz-Ruiz, Daniel Gil-Alós, Patricia del Moral, Adrián Fernández, Diana Sanjurjo, et al.


  • Open Access

    Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells

    by Corynn Kasap, Adila Izgutdina, Bonell Patiño-Escobar, Amrik Singh Kang, Nikhil Chilakapati, Naomi Akagi, Ananya Mishu Manoj, Haley Johnson, Tasfia Rashid, Juwita Werner, et al.

    Despite the success of BCMA-targeting CAR-Ts in multiple myeloma, patients with high-risk cytogenetic features still relapse most quickly and are in urgent need of additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target in other cancers, as a specifically upregulated cell surface antigen in high-risk myeloma tumors. We use a structure-guided design to define a CD27-based anti-CD70 CAR-T design that outperforms all tested scFv-based CARs, leading to >80-fold improved CAR-T expansion in vivo. Epigenetic analysis via machine learning predicts key transcription factors and transcriptional networks driving CD70 upregulation in high-risk myeloma. Dual-targeting CAR-Ts against either CD70 or BCMA demonstrate a potential strategy to avoid antigen escape-mediated resistance. Together, these findings support the promise of targeting CD70 with optimized CAR-Ts in myeloma as well as future clinical translation of this approach.